Who
Patricia S. Andrews
Director
Company insider
Files Form 4 as: Director, Oncolytics Biotech; Director, Geron; Director, Crescent Biopharma; Chief Commercial Officer, Incyte.
In numbers
- Trades disclosed
- 32
- Buys
- 2
- Sells
- 0
- Bought
- $143K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 21 Oct 2008
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,000 at $0.00 | filing |
| 25 Mar 2026filed 26 Mar 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,000 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $30K35,400 at $0.8557 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $30K35,400 at $0.86 | filing |
| 1 May 2024filed 1 May 2024 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 Dec 2023filed 2 Jan 2024 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | $12K5,191 at $2.36 | filing |
| 30 Sep 2023filed 3 Oct 2023 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | $12K8,167 at $1.50 | filing |
| 19 May 2023filed 22 May 2023 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 18 May 2022filed 20 May 2022 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 16 Nov 2021filed 18 Nov 2021 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Bought | $82K40,000 at $2.05 | filing |
| 18 May 2021filed 27 May 2021 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 18 May 2021filed 27 May 2021 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —5,250 at $0.00 | filing |
| 22 May 2020filed 27 May 2020 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 17 May 2019filed 21 May 2019 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 18 May 2018filed 21 May 2018 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 9 Jun 2017filed 12 Jun 2017 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 Jan 2012filed 23 Jan 2012 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,100 at $0.00 | filing |
| 19 Jan 2012filed 23 Jan 2012 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —93,900 at $0.00 | filing |
News
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% – Still a Buy?ONCY · dailypolitical.com · 16 Oct 2026Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentONCY · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Patricia S. Andrews; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.